Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Jonas Dyhrfjeld-Johnsen has been named chief development officer of Acousia Therapeutics. Most recently, Dyhrfjeld-Johnsen was head of pharmacology at Rewind Therapeutics.
Stewart Kay has been appointed to the role of chief business officer of Adaptate Biotherapeutics. Formerly, Kay was the chief business officer of Crescendo Biologics.
American Injectables has hired Ben Boling to assume the role of chief operating officer. Boling was most recently chief operating officer of Bio-Concept Laboratories.
Ascendis Pharma has appointed Mark Bach senior vice president of clinical development and medical affairs for endocrinology rare diseases. Bach most recently served as head of Asia Pacific medical sciences at Janssen Pharmaceuticals.
Boehringer Ingelheim has named Yew Looi Liew president of U.S. human pharma. Liew was formerly the corporate senior vice president and head of human pharma for the company’s emerging markets region.
David Pyrce, former senior vice president of strategy and chief commercial officer of NantKwest, has been named CEO of DevaCell.
Biopharmaceutical company DURECT has found its newest chief medical officer in Norman Sussman, a former associate professor of medicine and surgery at the Baylor College of Medicine.
Eagle Pharmaceuticals has appointed four new members to its clinical, formulations and commercialization team, including Judith Ng-Cashin to executive vice president and chief medical officer, John Kimmet to executive vice president of oncology and acute care marketing, Valentin Curt to senior vice president of clinical drug development and Gaozhong Zhu to senior vice president of pharmaceutical development. Prior to these appointments, Ng-Cashin was the chief medical officer of AoBiome Therapeutic, Kimmet was head of strategic planning and decision analysis at Bristol Myers Squibb, Curt was executive medical director of clinical R&D at Imbrium Therapeutics and Zhu was vice president and head of pharmaceutical development and manufacturing at Corvidia Therapeutics.
Karin Rosén has been named executive vice president of R&D and chief scientific officer of Horizon Therapeutics. Prior to joining Horizon, Rosén was the senior vice president of U.S. medical affairs at GlaxoSmithKline.
Mariana Nacht has been named chief scientific officer of LogicBio Therapeutics. Prior to this appointment, Nacht was chief scientific officer of Cereius. LogicBio has also promoted Kyle Chiang, the company’s vice president of product strategy, to the role of chief operating officer.
Torsten Hoffmann has been appointed global R&D director of Oryzon Genomics. Previously, Hoffmann was the senior vice president of drug discovery at Taros Chemicals.
Polyplus has named Mario Philips as the company’s newest CEO. Philips joins Polyplus from French biotech Polyneuros, where he also served as CEO.
David Wishart has been appointed to ProMIS Neurosciences’ scientific advisory board. Wishart is a professor in the departments of biological sciences and computing science at the University of Alberta.
QurAlis has appointed Angela Genge to the role of chief medical officer. Genge previously served as the director of the neuromuscular disease clinic and the neuropathic pain clinic at the Montreal Neurological Hospital and currently serves as the executive director of the hospital’s clinical research unit.
Marie Wikström Lindholm has been appointed to the role of senior vice president of molecular design at Silence Therapeutics. Lindholm was most recently the company’s vice president and head of technology innovation.
Paris-based genomics medicine company SparingVision has named Florence Lorget as chief development sciences officer and Rajiv Gangurde as chief technology officer. Most recently, Lorget served as senior director of nonclinical safety evaluation at Sangamo Therapeutics. Gangurde previously served as senior director and head of chemistry, manufacturing and controls at Voyager Therapeutics.
Trillium Therapeutics has hired Ingmar Bruns to the role of chief medical officer. Formerly, Bruns was senior vice president and head of clinical development at Pieris Pharmaceuticals.
Art Taveras, former chief scientific officer of CoMET Therapeutics, is now the chief scientific officer of X4 Pharmaceuticals.